September 24, 2013

ZEISS Expands Its Offering for Cancer Treatment: Targeted Radiotherapy Now also Available for Skin and Gastrointestinal Tumors

Expanded applications of ZEISS INTRABEAM receive approval in USA, Europe and China

As a radiation oncology platform, the INTRABEAM radiotherapy system from ZEISS now offers additional options for cancer treatment. It can now also be used in dermatology, gastroenterology and palliative cancer treatments.

DUBLIN, CA USA / JENA, GERMANY, 24 September 2013

"While our focus has been on intraoperative radiotherapy for breast cancer, we now also offer patented radiation technology for patients with skin or gastrointestinal tumors, or with metastases in the spine area," says Dr. Ludwin Monz, President and CEO of Carl Zeiss Meditec AG. With INTRABEAM radiotherapy, either the tumor itself, or the tumor margins, after removal of the tumor, are locally irradiated with a low energy 50 kV X-ray. "Patients who are potential candidates for this type of treatment receive radiation targeted directly to the diseased tissue with the dose and duration of the treatment adapted to the specific needs of each patient," Ludwin Monz continues. 

In the past 14 years ZEISS INTRABEAM® has been utilized around the world for more than 8,000 patients, predominantly for breast cancer. With more than 200 installed systems, ZEISS is now the market and innovation leader in intraoperative radiotherapy for breast cancer. The world's largest study on partial breast irradiation, TARGIT-A, was conducted exclusively with INTRABEAM. The study included 3451 patients in 33 international centers, half of whom received external beam radiotherapy (EBRT) and half targeted intraoperative radiotherapy (TARGIT). The study compared ZEISS INTRABEAM to traditional whole breast irradiation in women 45 years and over with invasive ductal carcinoma. The TARGIT-A trial demonstrated that for a select group of patients targeted intraoperative radiotherapy with ZEISS INTRABEAM Spherical Applicators at the time of lumpectomy to be non-inferior to traditional EBRT.

With INTRABEAM, unlike traditional radiotherapy, a low-energy X-ray source is brought into direct contact with the tumor or tumor margin. This means that the affected tissue is irradiated with a high degree of precision, thus reducing irradiation to healthy tissues and organs. Due to the low X-ray energy, INTRABEAM does not require any complex radiation shielding measures and is even suitable for mobile use.

For non-melanoma skin cancers, a new radiotherapy treatment option with the INTRABEAM Surface Applicator is now available for patients, particularly those with high surgical risk or those requiring treatment on cosmetically relevant areas where surgery is not desired. Together with the new INTRABEAM Flat Applicator and the Needle Applicator, the benefits of INTRABEAM treatment – precise radiation dose targeted directly to the diseased area – can now be utilized for other types of cancer such as spinal cancers.

Press contact
Jann Gerrit Ohlendorf
Group Communications
Carl Zeiss Meditec AG
Phone +49 (0)3641220-331
Email: press .meditec @zeiss .com 

Alice Swinton
Group Communications
Carl Zeiss Meditec, Inc.
Phone +1 925 557 4317
Email: alice .swinton @zeiss .com

For investors 
Henriette Meyer
Investor Relations
Carl Zeiss Meditec AG
Phone +49 (0)3641220-106
Email: investors .meditec @zeiss .com